LAIV works by introducing weakened viruses into the nasal passages, which mimic a natural infection and stimulate the body's immune system to produce antibodies. These antibodies help protect against future infections by the influenza virus. The vaccine is designed to be cold-adapted, meaning the viruses can replicate in the cooler environment of the nose but not in the warmer temperatures of the lower respiratory tract, reducing the risk of illness.
